Semaglutide is a prescription medication in most countries. This guide is for educational purposes only. Never use semaglutide without physician supervision — it has meaningful drug interactions and contraindications including personal/family history of medullary thyroid carcinoma and MEN2 syndrome.
Semaglutide is a GLP-1 receptor agonist — a synthetic analogue of glucagon-like peptide-1, an endogenous incretin hormone produced in the gut after eating. It was originally developed by Novo Nordisk for type 2 diabetes management and has since become one of the most prescribed and most studied drugs in the world following its approval for chronic weight management.
Its mechanisms are multifactorial and extend far beyond simple appetite suppression:
| Form | Approved Use | Max Dose | Notes |
|---|---|---|---|
| Ozempic (branded) | Type 2 diabetes | 2.0 mg/week | Widely prescribed off-label for weight loss; pen injector |
| Wegovy (branded) | Chronic weight management | 2.4 mg/week | Highest approved dose; same molecule as Ozempic |
| Compounded semaglutide | Research / off-label | Variable | Significantly lower cost; quality varies enormously — source from licensed compounding pharmacies only with COA verification |
| Rybelsus (oral) | Type 2 diabetes | 14 mg/day | Oral tablet; lower bioavailability than injectable; must be taken fasted |
The compounded semaglutide market has significant quality variation. Multiple FDA warnings have been issued about underdosed, contaminated, or mislabeled products. Use only licensed 503B outsourcing facilities with verifiable COAs. The Emerald Wellness vendor directory includes only verified sources.
Slow titration is the most important variable in semaglutide tolerability. The majority of people who discontinue semaglutide do so because of nausea — and the majority of those cases involve going too fast. The standard titration protocol:
If you experience significant nausea at any dose, do not advance to the next step. Stay at the current dose for an additional 4 weeks. GI adaptation continues with time — most people find their nausea resolves or becomes manageable within 2–4 weeks of any given dose.
| Goal | Target Dose | Rationale |
|---|---|---|
| Aggressive weight loss (BMI >30) | 1.7–2.4 mg/week | SUSTAIN-6 and STEP trials show dose-dependent weight loss up to maximum dose |
| Moderate weight loss / body recomposition | 0.5–1.0 mg/week | Significant appetite suppression; lower side effect burden; sustainable long-term |
| Metabolic optimization (insulin sensitivity) | 0.5–1.0 mg/week | HbA1c and fasting insulin improvement at lower doses; may not require maximum dose |
| Cardiovascular protection (longevity) | 0.5–1.0 mg/week | SELECT trial cardiovascular benefits appear at standard doses; higher doses not required for CV protection |
| Neuroprotection (emerging use) | 0.5 mg/week | GLP-1 brain effects under investigation; use lowest effective dose given preliminary nature of this evidence |
The most significant underreported concern with semaglutide is muscle mass loss. DEXA scan studies show that approximately 25–40% of weight lost on GLP-1 agonists is lean mass — not fat — in users who don't take specific countermeasures. This is not unique to semaglutide; it's a consequence of significant caloric restriction without adequate protein and resistance training stimulus.
This matters enormously for long-term health: muscle mass is one of the strongest predictors of all-cause mortality and healthspan. Losing substantial lean mass while losing fat undermines the longevity benefits of weight loss.
Semaglutide significantly reduces appetite and food volume — which makes every calorie count more, not less. Nutritional quality becomes critical when total food intake is reduced:
| Principle | Target | Why |
|---|---|---|
| Protein | 1.6–2.0g per kg bodyweight | Muscle preservation; satiety; thermic effect of food |
| Minimum calories | 1,200–1,500 kcal/day | Below this, muscle loss accelerates and micronutrient deficiency becomes likely |
| Meal structure | Protein-first at every meal | Ensures protein goals met before appetite suppression terminates the meal |
| Fiber | 25–35g/day | Constipation prevention; microbiome health; glucose control synergy with semaglutide |
| Alcohol | Minimize or eliminate | Semaglutide + alcohol significantly increases pancreatitis risk; empty calories worsen muscle loss |
| Fatty/fried food | Avoid during titration | Dramatically worsens nausea and gastroparesis-like symptoms |
| Supplement | Dose | Purpose |
|---|---|---|
| Creatine Monohydrate | 5 g/day | Muscle preservation during caloric restriction — most important add-on |
| Whey or Casein Protein | To hit 1.6g/kg goal | Protein supplementation when food intake is suppressed |
| HMB | 3 g/day (split 3x) | Anti-catabolic; leucine metabolite; prevents muscle breakdown |
| Magnesium Glycinate | 400 mg/night | Constipation prevention; sleep; depleted by reduced food intake |
| Vitamin D3 + K2 | 5,000 IU + 150mcg | Often deficient; critical for muscle function and immune health during weight loss |
| Zinc Bisglycinate | 25–30 mg/day | Depleted with reduced food intake; critical for testosterone maintenance during weight loss |
| Electrolyte Complex | Daily | Sodium, potassium, magnesium — all depleted with reduced food intake and potential GI losses |
| Berberine | 500mg 3x/day with meals | Synergistic insulin sensitization; amplifies metabolic effects of semaglutide |
| GLP-1 Probiotic Strains | Per product dosing | Lactobacillus reuteri and specific strains may enhance endogenous GLP-1 production, complementing semaglutide |
Semaglutide is approved for long-term continuous use in the context of diabetes and chronic weight management. However, many biohackers and longevity practitioners use it cyclically for metabolic maintenance:
| Approach | Protocol | Best For |
|---|---|---|
| Continuous use | Ongoing maintenance dose (0.5–1.0 mg/week) | T2D, significant obesity, cardiovascular risk reduction |
| Goal-based cycling | Use until goal weight achieved; taper off; resume if weight regained by >5% | Body recomposition goals without long-term dependency |
| Metabolic reset cycle | 6–12 months on, assess off-drug metabolic health, resume if needed | Insulin resistance reversal; biohackers using for metabolic optimization |
| Seasonal maintenance | Lower dose (0.25–0.5 mg/week) continuously for cardiovascular and neuroprotective benefits | Longevity-focused users prioritizing CV and cognitive protection over weight loss |
The majority of users regain weight after discontinuing semaglutide without addressing the underlying behavioral and metabolic factors. Semaglutide works best as a tool to enable habit change, not as a permanent pharmacological fix. Use the appetite suppression window to build protein-first eating habits, establish consistent resistance training, and address sleep and stress — so the metabolic improvements persist after discontinuation.
Yes — in the US, UK, EU, and most countries, semaglutide requires a prescription. Branded Ozempic and Wegovy require physician prescription. Compounded semaglutide from licensed pharmacies also technically requires a prescription in most jurisdictions. Telehealth platforms have made access significantly easier — a physician consultation is still required.
Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1 and GIP agonist — it activates two incretin receptors instead of one. Clinical trials show tirzepatide produces greater average weight loss than semaglutide (20–22% body weight vs 15–17%). However, semaglutide has a longer safety and efficacy track record. Both are strong choices; tirzepatide may be preferred for maximum weight loss, semaglutide for its broader cardiovascular evidence base.
Once weekly SubQ injection — abdomen, upper thigh, or upper arm. Rotate sites weekly. Use the shortest available needle (4–5mm). Inject at room temperature. Pinch 2 inches of skin, insert needle at 45–90 degrees, inject slowly, hold for 10 seconds before withdrawing. Dispose in sharps container.
Significant weight loss — particularly reduction in visceral fat — typically improves testosterone in men and normalizes estrogen in both sexes. GLP-1 receptors are present in the ovaries and testes, and early research suggests direct hormonal modulation beyond weight effects. Monitor total/free testosterone and estradiol before and after 90 days of use.
Log your weekly dose, titration schedule, weight, and metabolic labs. Get interaction checking for all your stack supplements, and let the Health Intelligence Advisor personalize your muscle preservation protocol.
Join the Waitlist →